Exhibit 99.1

Interpace
Biosciences Announces Third Quarter 2026 Financial and Business Results
| ● | Q3
Revenue of $10.4 million |
| ● | Q3
Thyroid volume year-over-year increase of 7% |
| ● | Q3
Thyroid revenue year-over-year increase of 18% |
| ● | Trailing
twelve-month thyroid revenue of $38.0 million, an increase of 13% on a comparable thyroid-only
basis |
PARSIPPANY,
NJ, November 16, 2026 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCID:
IDXG) today announced financial results for the third quarter ended September 30, 2026 and provided a business and financial update.
Interpace
generated Q3 2026 revenue of $10.4 million, up 18% year-over-year, a loss from continuing operations of $1.5 million compared to income
from continuing operations of $1.0 million in the prior year, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The loss
from continuing operations of $1.5 million included approximately $4.1 million of non-recurring stock compensation costs and non-recurring
legal expenses.
As
previously disclosed, the Company discontinued its PancraGEN® pancreatic testing business in May 2025 and now operates
as a thyroid-only molecular diagnostics company. Prior-year reported results therefore include PancraGEN revenue and related costs, while
the Company’s current-year results do not. Reported year-over-year comparisons for the nine-month period are affected by this change,
and the Pro Forma prior-year results presented below exclude PancraGEN in order to show the underlying thyroid business on a consistent
basis. Beginning with the third quarter of 2026, reported year-over-year comparisons will be presented on a directly comparable thyroid-only
basis, as the prior-year comparative periods no longer include PancraGEN.
“The
Company continued to convert revenue growth into margin expansion in the third quarter, reflecting the operating leverage we have built
into the business,” said Chris McCarthy, Chief Financial Officer. “Gross margin expanded to 69% in Q3 2026, up from 62% in
Q3 2025 and 63% on a Pro Forma basis, supported by an 11% increase in average thyroid revenue per test and continued efficiency gains
in our laboratory. That gross margin expansion carried through to the bottom line: Adjusted EBITDA margin improved to 20% from 14% in
the prior year quarter and 17% on a Pro Forma basis, with Adjusted EBITDA increasing to $2.1 million from $1.3 million. Year-to-date,
gross margin has expanded to 66% from 59%, and Adjusted EBITDA margin to 15% from 10%, compared to the prior year period on a Pro Forma
basis. Q3 2026 revenue grew 18% to $10.4 million, or 15% on a Pro Forma basis, on 7% growth in thyroid test volume. These results reflect
steady execution across our commercial and operations teams, and the clinical value physicians continue to see in ThyGeNEXT®
and ThyraMIR®v2.”
McCarthy
added, “Our debt-free balance sheet continues to support meaningful investment in laboratory automation, AI-enabled productivity
initiatives across our workflow, and research and development to advance our pipeline. Those investments are already showing up in our
laboratory, where average ThyGeNEXT® and ThyraMIR®v2 turnaround time improved approximately 11% in the
first nine months of 2026 compared to the prior year period. We are scaling operating leverage in line with volume growth without a corresponding
increase in headcount, which we expect will support continued margin expansion.”
“The
third quarter demonstrates the durability of the business we built through last year’s transition and the operating discipline
we will carry through the remainder of 2026 and into 2027,” said Tom Burnell, President and CEO. “We see the same characteristics
in Q3 2026 that defined our 2025 performance — disciplined execution, expanding clinical adoption, and a steady cadence of operational
improvement. We continue to believe our combination approach — ThyGeNEXT® for mutation detection and ThyraMIR®v2
for microRNA pathway insights — gives physicians the confidence and clarity they need to make informed patient-management decisions.”
All
share and per share numbers in this release give effect to the one-for-five reverse stock split effected on August 27, 2026.
Pancreatic
Cancer Program Update
Interpace
is seeking to extend the next-generation sequencing and microRNA technology platforms behind ThyGeNEXT® and ThyraMIR®v2
into pancreatic cancer. The program design includes an extensive genomic panel and proprietary microRNA classification aligned with National
Comprehensive Cancer Network (NCCN) guidelines. Together, these technologies are intended to provide decision-making support to clinicians,
including medical oncologists, for pancreatic cancer detection, classification, and neoadjuvant treatment selection. Analytical validation
of the panel design is underway, with clinical validation and utility studies planned across 2026 and 2027, and reimbursement and launch
activities to follow. This new product is in development, not yet available for clinical use, and has not been cleared or approved by
the U.S. Food and Drug Administration. There can be no assurance that development will be completed on the anticipated timeline or at
all, and the Company does not expect the program to contribute revenue in 2026 or 2027.
Third
Quarter 2026 Financial Performance
For
the Third Quarter of 2026 as Compared to the Third Quarter of 2025:
| ● | Revenue
was $10.4 million, an increase of 18% from $8.8 million for the prior year quarter. |
| ● | Gross
Profit percentage was 69% compared to 62% for the prior year quarter. |
| ● | Operating
loss was $2.4 million versus operating income of $1.1 million in the prior year quarter. |
| ● | Loss
from continuing operations was $1.5 million versus income from continuing operations of $1.0
million in the prior year quarter. |
| ● | Loss
from continuing operations for the third quarter of 2026 included approximately $4.1 million
of non-recurring stock compensation costs and non-recurring legal expenses. These charges
are excluded from Adjusted EBITDA. |
| ● | Adjusted
EBITDA was $2.1 million versus $1.3 million in the prior year quarter. |
| ● | Adjusted
EBITDA margin was approximately 20% compared to approximately 14% for the prior year quarter. |
| ● | Q3
2026 cash collections totaled $9.1 million compared to $10.0 million in the prior year quarter. |
Year-to-Date
and Trailing Twelve-Month Performance
| ● | Revenue
for the nine months ended September 30, 2026 was $28.5 million, a decrease from $29.5 million
for the prior year period and an increase of 13% from $25.3 million for the prior year period
Pro Forma. |
| ● | Gross
Profit percentage for the nine months ended September 30, 2026 was 66% compared to 61% for
the prior year period and 59% for the prior year period Pro Forma. |
| ● | Loss
from continuing operations for the nine months ended September 30, 2026 was $0.4 million
compared to income from continuing operations of $2.2 million for the prior year period and
$1.0 million for the prior year period Pro Forma, and included approximately $4.4 million
of non-recurring stock compensation costs and non-recurring legal expenses. |
| ● | Adjusted
EBITDA for the nine months ended September 30, 2026 was $4.4 million, or 15% of revenue,
compared to $3.7 million, or 13% of revenue for the prior year period and $2.5 million, or
10% of revenue, for the prior year period Pro Forma. |
| ● | On
a trailing twelve-month basis, thyroid revenue was $38.0 million, an increase of approximately
13% over the comparable prior twelve-month period Pro Forma, on trailing twelve-month thyroid
test volume growth of approximately 9%. |
Management
uses a non-GAAP Pro Forma income statement to help evaluate the results of our performance. The Pro Forma income statement for 2025 reflects
the Company’s current business structure as a thyroid-only diagnostics testing company and excludes revenue and related costs from
PancraGEN, which was discontinued in May 2025. These adjustments are presented for comparability purposes only and do not represent GAAP
financial measures. Investors should review GAAP results alongside these pro forma figures for a complete understanding of performance.
A reconciliation of GAAP and these pro forma figures is presented below.
About
Interpace Biosciences
Interpace
Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain
from early diagnosis and prognostic planning to targeted therapeutic applications.
Clinical
services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services
for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management.
Interpace has two commercialized molecular tests: ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules
utilizing a next-generation sequencing assay and ThyraMIR®v2, used in combination with ThyGeNEXT®, for
the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.
For
more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial
and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,”
“estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,”
“potential,” “may,” “could,” “might,” “will,” “should,” “approximately”
or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are
based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive
and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which
are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may
cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements,
including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows, and net income, as well
as Pro Forma financial results and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating
losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s
dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including
its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption
in processing or transmitting such claims, and the Company’s revenue recognition being based in part on estimates for future collections
which estimates may prove to be incorrect.
Additionally,
all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2025, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed
with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not
be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except
as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com
INTERPACE
BIOSCIENCES, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(in
thousands, except per share data)
| | |
Three Months
Ended | | |
Nine Months
Ended | |
| | |
September
30, | | |
September
30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
(unaudited) | | |
(unaudited) | |
| | |
| | |
| | |
| | |
| |
| Revenue, net | |
$ | 10,373 | | |
$ | 8,756 | | |
$ | 28,537 | | |
$ | 29,504 | |
| Cost of revenue | |
| 3,193 | | |
| 3,317 | | |
| 9,799 | | |
| 11,418 | |
| Gross Profit | |
| 7,180 | | |
| 5,439 | | |
| 18,738 | | |
| 18,086 | |
| | |
| | | |
| | | |
| | | |
| | |
| Sales and marketing | |
| 2,704 | | |
| 2,087 | | |
| 7,088 | | |
| 7,811 | |
| Research and development | |
| 160 | | |
| 150 | | |
| 461 | | |
| 500 | |
| General and administrative | |
| 6,716 | | |
| 2,057 | | |
| 12,143 | | |
| 7,268 | |
| Total
operating expenses | |
| 9,580 | | |
| 4,294 | | |
| 19,692 | | |
| 15,579 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating (loss) income | |
| (2,400 | ) | |
| 1,145 | | |
| (954 | ) | |
| 2,507 | |
| Note payable interest expense | |
| - | | |
| (30 | ) | |
| - | | |
| (156 | ) |
| Other income (expense),
net | |
| 15 | | |
| (115 | ) | |
| 33 | | |
| (112 | ) |
| (Loss) income from continuing
operations before tax | |
| (2,385 | ) | |
| 1,000 | | |
| (921 | ) | |
| 2,239 | |
| Benefit (provision) for
income taxes | |
| (884 | ) | |
| (11 | ) | |
| (517 | ) | |
| 7 | |
| (Loss) income from continuing
operations | |
| (1,501 | ) | |
| 1,011 | | |
| (404 | ) | |
| 2,232 | |
| | |
| | | |
| | | |
| | | |
| | |
| Loss from discontinued
operations, net of tax | |
| (109 | ) | |
| (100 | ) | |
| (327 | ) | |
| (314 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net
(loss) income | |
$ | (1,610 | ) | |
$ | 911 | | |
| (731 | ) | |
| 1,918 | |
| | |
| | | |
| | | |
| | | |
| | |
| Basic income (loss) per share of common stock: | |
| | | |
| | | |
| | | |
| | |
| From continuing operations | |
$ | (0.26 | ) | |
$ | 1.14 | | |
$ | (0.08 | ) | |
$ | 2.52 | |
| From
discontinued operations | |
| (0.02 | ) | |
| (0.11 | ) | |
| (0.06 | ) | |
| (0.35 | ) |
| Net
income (loss) per basic share of common stock | |
$ | (0.28 | ) | |
$ | 1.03 | | |
$ | (0.14 | ) | |
$ | 2.17 | |
| | |
| | | |
| | | |
| | | |
| | |
| Diluted income (loss) per
share of common stock: | |
| | | |
| | | |
| | | |
| | |
| From continuing operations | |
$ | (0.26 | ) | |
$ | 0.18 | | |
$ | (0.08 | ) | |
$ | 0.40 | |
| From
discontinued operations | |
| (0.02 | ) | |
| (0.02 | ) | |
| (0.06 | ) | |
| (0.06 | ) |
| Net
income (loss) per diluted share of common stock | |
$ | (0.28 | ) | |
$ | 0.16 | | |
$ | (0.14 | ) | |
$ | 0.35 | |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of common shares and common share equivalents
outstanding: | |
| | | |
| | | |
| | | |
| | |
| Basic | |
| 5,705 | | |
| 885 | | |
| 5,210 | | |
| 885 | |
| Diluted | |
| 5,705 | | |
| 5,539 | | |
| 5,210 | | |
| 5,539 | |
Selected
Balance Sheet Data
($
in thousands)
| | |
September
30, | | |
December
31, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Cash and cash equivalents | |
$ | 2,929 | | |
$ | 2,505 | |
| | |
| | | |
| | |
| Total current assets | |
| 13,286 | | |
| 9,900 | |
| Total current liabilities | |
| 6,438 | | |
| 5,103 | |
| | |
| | | |
| | |
| Total assets | |
| 37,468 | | |
| 33,838 | |
| Total liabilities | |
| 12,777 | | |
| 11,475 | |
| Total stockholders’ equity | |
| 24,691 | | |
| 22,363 | |
Selected
Cash Flow Data
($
in thousands)
| | |
For the Nine
Months Ended | |
| | |
September
30, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Net (loss) income | |
$ | (731 | ) | |
$ | 1,918 | |
| | |
| | | |
| | |
| Net cash provided by operating activities | |
$ | 1,351 | | |
$ | 3,693 | |
| Net cash used in investing activities | |
| (567 | ) | |
| (318 | ) |
| Net cash used in financing
activities | |
| (360 | ) | |
| (3,413 | ) |
| Change in cash and cash equivalents | |
| 424 | | |
| (38 | ) |
| Cash and cash equivalents
– beginning | |
| 2,505 | | |
| 1,461 | |
| Cash and cash equivalents
– ending | |
$ | 2,929 | | |
$ | 1,423 | |
Reconciliation
of Pro Forma (Unaudited)
(in
thousands, except per share data)
| | |
Nine Months
Ended September 30, 2025 | |
| | |
| | |
PancraGEN | | |
| |
| | |
As
Reported | | |
Direct
Costs* | | |
Pro
Forma | |
| | |
| | |
| | |
| |
| Revenue, net | |
$ | 29,504 | | |
$ | 4,193 | | |
$ | 25,311 | |
| Cost of revenue | |
| 11,418 | | |
| 1,023 | | |
| 10,395 | |
| Gross Profit | |
| 18,086 | | |
| 3,170 | | |
| 14,916 | |
| | |
| | | |
| | | |
| | |
| Sales and marketing | |
| 7,811 | | |
| 1,653 | | |
| 6,158 | |
| Research and development | |
| 500 | | |
| 100 | | |
| 400 | |
| General and administrative | |
| 7,268 | | |
| 193 | | |
| 7,075 | |
| Total
operating expenses | |
| 15,579 | | |
| 1,946 | | |
| 13,633 | |
| | |
| | | |
| | | |
| | |
| Operating income | |
| 2,507 | | |
| 1,224 | | |
| 1,283 | |
| | |
| | | |
| | | |
| | |
| Note payable interest | |
| (156 | ) | |
| - | | |
| (156 | ) |
| Other
expense, net | |
| (112 | ) | |
| - | | |
| (112 | ) |
| Income from continuing
operations before tax | |
| 2,239 | | |
| 1,224 | | |
| 1,015 | |
| Provision for income taxes | |
| 7 | | |
| - | | |
| 7 | |
| Income from continuing
operations | |
| 2,232 | | |
| 1,224 | | |
| 1,008 | |
| | |
| | | |
| | | |
| | |
| Loss
from discontinued operations, net of tax | |
| (314 | ) | |
| - | | |
| (314 | ) |
| | |
| | | |
| | | |
| | |
| Net
income | |
$ | 1,918 | | |
$ | 1,224 | | |
$ | 694 | |
| | |
| | | |
| | | |
| | |
| Basic income (loss) per share of common stock: | |
| | | |
| | | |
| | |
| From continuing operations | |
$ | 2.52 | | |
$ | 1.38 | | |
$ | 1.14 | |
| From
discontinued operations | |
| (0.35 | ) | |
| - | | |
| (0.35 | ) |
| Net
income (loss) per basic share of common stock | |
$ | 2.17 | | |
$ | 1.38 | | |
$ | 0.78 | |
| | |
| | | |
| | | |
| | |
| Diluted income (loss) per share of common stock: | |
| | | |
| | | |
| | |
| From continuing operations | |
$ | 0.40 | | |
$ | 0.22 | | |
$ | 0.18 | |
| From
discontinued operations | |
| (0.06 | ) | |
| - | | |
| (0.06 | ) |
| Net
income (loss) per diluted share of common stock | |
$ | 0.35 | | |
$ | 0.22 | | |
$ | 0.13 | |
| | |
| | | |
| | | |
| | |
| Weighted average number of common shares and common share equivalents
outstanding: | |
| | | |
| | | |
| | |
| Basic | |
| 885 | | |
| 885 | | |
| 885 | |
| Diluted | |
| 5,539 | | |
| 5,539 | | |
| 5,539 | |
*
PancraGEN Direct Costs represent only direct costs associated with the operations of PancraGEN testing, with no allocations or estimates
of corporate, shared, or overhead expenses included.
Reconciliation
of Adjusted EBITDA (Unaudited)
($
in thousands)
| | |
Three Months
Ended | | |
Nine Months
Ended | |
| | |
September
30, | | |
September
30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| (Loss) income from continuing operations
(GAAP Basis) | |
$ | (1,501 | ) | |
$ | 1,011 | | |
$ | (404 | ) | |
$ | 2,232 | |
| Depreciation and amortization | |
| 141 | | |
| 111 | | |
| 386 | | |
| 307 | |
| Stock-based compensation | |
| 3,993 | | |
| 7 | | |
| 4,001 | | |
| 31 | |
| Non-recurring legal expenses | |
| 234 | | |
| - | | |
| 614 | | |
| - | |
| Severance & related expense | |
| - | | |
| - | | |
| - | | |
| 692 | |
| Asset impairment - lab supplies | |
| - | | |
| - | | |
| - | | |
| 198 | |
| Loss on sale of asset | |
| 104 | | |
| - | | |
| 104 | | |
| - | |
| Lab supplies write-off | |
| - | | |
| - | | |
| 217 | | |
| - | |
| Income tax (benefit) expense | |
| (884 | ) | |
| (11 | ) | |
| (517 | ) | |
| 7 | |
| Note payable interest | |
| - | | |
| 30 | | |
| - | | |
| 156 | |
| Other income/expense, net | |
| (15 | ) | |
| 10 | | |
| (33 | ) | |
| 25 | |
| Change in fair value of
note payable | |
| - | | |
| 105 | | |
| - | | |
| 87 | |
| Adjusted EBITDA | |
$ | 2,072 | | |
$ | 1,263 | | |
$ | 4,368 | | |
$ | 3,735 | |
Non-GAAP
Financial Measures
In
addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided
certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures,
when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing
business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation,
allows investors to view our financial results in the way that management views financial results.
In
this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash
flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization,
non-cash stock-based compensation, severance expense, asset impairment-lab supplies, non-recurring legal expenses, interest and taxes,
and other non-cash expenses including change in fair values of notes payable. The table above includes a reconciliation of this non-GAAP
financial measure to the most directly comparable GAAP financial measure.